<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841113</url>
  </required_header>
  <id_info>
    <org_study_id>ABACAS1</org_study_id>
    <nct_id>NCT00841113</nct_id>
  </id_info>
  <brief_title>Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer</brief_title>
  <official_title>Phase III Study of the Comparison of Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer. A One Year Randomised, Open Label, Multi-Centre Phase III Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Speciality European Pharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Speciality European Pharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients
      with advanced or metastatic prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria

        -  Males over 18 with documented advanced or metastatic prostate cancer

      Outcome measures

        -  Comparative castration rates one week after starting therapy

        -  Degree of testosterone surge in the first month of treatment.

        -  Maintenance of medical castration during one year of therapy.

        -  Comparison of the treatments on QTc prolongation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Actual">February 2003</completion_date>
  <primary_completion_date type="Actual">February 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early castration rates</measure>
    <time_frame>One week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maintenance of medical castration</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1 Abarelix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigative drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Goserelin plus bicalutamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abarelix</intervention_name>
    <description>100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter</description>
    <arm_group_label>1 Abarelix</arm_group_label>
    <other_name>Plenaxis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin plus Bicalutamide</intervention_name>
    <description>Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months</description>
    <arm_group_label>2 Goserelin plus bicalutamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven prostate cancer and not previously treated with hormones

          -  Evidance of advanced disease or metastases

          -  Life expentancy of at least 3 months

          -  Normal serum testosterone levels

          -  Written informed consent

        Exclusion Criteria:

          -  Previous endocrine or cytoxic theapy for prostate cancer

          -  Known tumour complication of prostate cancer which owuld require immediate treatment

          -  Another malignancy other than basal cell cancer

          -  History of significant drug hypersensitivity to either LHRH agonists or GnRH
             antagonists.

          -  Congenital or acquired coagulation disorders contraindicating intramuscular injections

          -  Pagets disease of the bone

          -  QTcB &gt; 450 msec at Day - 14
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frans M J Debruyne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Nijmegen</affiliation>
  </overall_official>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>February 10, 2009</last_update_submitted>
  <last_update_submitted_qc>February 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Speciality European Pharma Limited</name_title>
    <organization>SEP</organization>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Advanced</keyword>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Abarelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

